1.Measured by its ability to agglutinate human red blood cells. The ED50 for this effect is typically 3-30μg/mL. 2.Loaded Recombinant Human Thy1/CD90 Protein, His Tag on NTA Biosensor, can bind Recombinant Human Galectin-1 Protein with an affinity constant of 46.9 nM as determined in BLI assay (Routinely tested).

Galectin-1 Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 15 kDa and the accession number is A0A384MR27.

Human

E. coli

lectin, galactoside-binding, soluble, 1,GBP,Galectin-1,GAL1

A DNA sequence encoding the human Galectin 1 (NP_002296.1) (Met 1-Asp135) was expressed. Predicted N terminal: Ala 2

> 98 % as determined by SDS-PAGE

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Galectin-1 (Gal-1, GAL1), is a member of the galectins, a family of animal lectins ranging from Caenorhabditis elegans to humans, which is defined by their affinity for beta-galactosides and by significant sequence similarity in the carbohydrate-binding site. It is a homodimer with a subunit molecular mass of 14.5 kDa, which contains six cysteine residues per subunit. The cysteine residues should be in a free state to maintain a molecular structure that is capable of showing lectin activity. This endogenous lectin widely expressed at sites of inflammation and tumor growth has been postulated as an attractive immunosuppressive agent to restore immune cell tolerance and homeostasis in autoimmune and inflammatory settings. On the other hand, galectin-1 contributes to different steps of tumor progression including cell adhesion, migration, and tumor-immune escape, suggesting that blockade of galectin-1 might result in therapeutic benefits in cancer. Several potential glycoprotein ligands for galectin-1 have been identified, including lysosome-associated membrane glycoproteins and fibronectin, laminin, as well as T-cell glycoproteins CD43 and CD45. Evidence points to Gal-1 and its ligands as one of the master regulators of such immune responses as T-cell homeostasis and survival, T-cell immune disorders, inflammation, and allergies as well as host-pathogen interactions.